Lumier Pharma LLC is a domestic manufacturer of pharmaceuticals. The company was established in 2009 in Kyiv, Ukraine. The product mix of medications registered in Ukraine consists of 14 items of medicines with varied pharmacological actions and production forms. Lumier Pharma LLC holds Medication Manufacturer License No. AB 578997 in which EU GMP requirements have been incorporated.
The company’s main activities embrace the production of vital prescription medicines for the treatment of oncological diseases, tuberculosis, blood diseases, and varieties of chronic viral hepatitis.
Marking and secondary packaging for “in bulk” products into:
Lumier Pharma LLC provides medication and medical-purpose goods packing and repacking services in conformity with all Ukrainian legislation and EU GMP requirements.
The company’s top-priority efforts are directed at the establishment and development of long-term partner relations with the world’s leading pharmaceutical companies within the framework of the import substitution policy in Ukraine aimed at the improvement of accessibility of high quality medicines for all patients. In 2010, work was commenced on the implementation of the mutual social project launched in collaboration with the global pharmaceuticals manufacturer, F.Hoffmann-La Roche Ltd., aimed at the production of the following biotechnological medicines in Ukraine: PEGFERON, PEG-interferon alpha-2a for the treatment of chronic viral hepatitis (B and C), RITUXIM (rituximab) for the treatment of hematological diseases, TRASTUMAB (trastuzumab) for mammary gland cancer treatment.
Lumier Pharma, a domestic manufacturer of pharmaceuticals, pursues the mission of providing the residents of Ukraine with groundbreaking import-substituting high-quality medications designated for the treatment of socially significant and societally hazardous diseases in conformity with internationally established treatment standards.